\nEdwards Lifesciences (NYSE: EW) will outline its patient-focused strategy and share financial guidance during its annual investor conference. Entering 2026 with momentum for sustainable differentiated growth, Edwards is uniquely positioned with leading therapies across its core structural heart innovations for patients with aortic stenosis (AS), mitral regurgitation (MR), tricuspid regurgitation (TR) and pulmonic diseases, and expanding into emerging opportunities to advance treatments for aortic regurgitation (AR) and structural heart failure.\n<\/p>\n
\n\u201cAs we enter 2026, we are poised for sustainable growth and long-term value creation,\u201d said Bernard Zovighian, Edwards\u2019 CEO. \u201cFor the more than 20 million structural heart patients worldwide, we are continuing to bring novel and differentiated innovations and world-class evidence to transform care. In addition, we are excited to pioneer therapies for the many structural heart patient groups currently unaddressed today, such as those with asymptomatic AS and those with mitral, tricuspid or aortic regurgitation in need of a transcatheter replacement. Edwards is the only company committed to delivering first-of-its-kind innovations for all of these patients, leveraging our 65 years of leadership and valve expertise. This approach underscores our unwavering commitment to creating long-term value for patients, physicians, health systems and shareholders.\u201d\n<\/p>\n
Highlights of today\u2019s conference include:<\/b><\/p>\n Topics to be discussed at today\u2019s conference include:<\/b><\/p>\n Transcatheter Aortic Valve Replacement (TAVR) <\/b>\u2013 Edwards\u2019 TAVR is positioned as the global benchmark, entering a new era of proactive disease management. The company\u2019s SAPIEN platform, with new indications and proven durability, remains the best-in-class therapy for lifetime management of patients with severe AS. SAPIEN is also the most studied valve, with more than 15 years of distinguished clinical trials involving over 10,000 patients, 10 New England Journal of Medicine<\/i> publications and 1.2 million patients treated around the world. Edwards\u2019 leadership strategy of differentiated innovation, world-class evidence generation and indication expansion is driving guideline and policy evolution and improved patient access and long-term adoption of the SAPIEN platform.\n<\/p>\n \nAnticipated upcoming milestones include:\n<\/p>\n Transcatheter Mitral and Tricuspid Therapies (TMTT)<\/b> \u2013 Edwards is advancing its vision to meet the complex unmet needs of patients with mitral and tricuspid disease with a differentiated portfolio comprised of repair and replacement technologies. The company has successfully commercialized a unique portfolio of therapies, including the PASCAL, EVOQUE and SAPIEN M3 systems, transforming care by enabling personalized therapy. At the same time, the company remains committed to its strategy of transformative product innovation, robust and expanding clinical evidence to support approvals and adoption, as well as comprehensive support to ensure excellent real-world patient outcomes.\n<\/p>\n \nAnticipated upcoming milestones include:\n<\/p>\n Surgical <\/b>\u2013 Edwards remains committed to advancing its leadership in surgical therapies and transforming patients\u2019 lives globally with leading surgical innovations. The company is focused on identifying and solving critical unmet needs in cardiac surgery to help patients live longer, healthier and more active lives. In 2026, Edwards will continue to drive adoption of its RESILIA tissue portfolio, the standard of tissue durability, including the INSPIRIS, MITRIS and KONECT platforms.\n<\/p>\n \nAnticipated upcoming milestones include:\n<\/p>\n Structural Heart Failure <\/b>\u2013 Edwards plans to establish a new data-driven, patient-engaged standard of care with its implantable pressure sensor guided management solutions, a meaningful long-term opportunity for patients suffering from heart failure. In 2026 and beyond, Edwards will continue to invest internally in R&D, and externally in adjacent therapies, to transform patient care while building its team and deploying clinician and patient education and awareness.\n<\/p>\n Transcatheter Aortic Valve Replacement for Aortic Regurgitation (TAVR-AR) <\/b>\u2013 AR is a deadly and progressive disease that affects a significant and growing number of patients with limited treatment options. As the pioneer in valve innovation, Edwards is well-positioned to lead this next frontier of aortic valve disease treatment and expects this to be the beginning of a long-term, iterative strategy similar to TAVR for AS.\n<\/p>\n 2026 Guidance<\/span><\/b><\/p>\n\n
\n
\n
\n
\n
\n
\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20251204308588\/en\/2148134\/3\/Preferred_Edwards_Logo.jpg\"){kind=logo}
<\/td>\n<\/tr>\n